Identification of Molecular Interactions Between a Chemokine Receptor and Ligand
趋化因子受体和配体之间分子相互作用的鉴定
基本信息
- 批准号:7511698
- 负责人:
- 金额:$ 2.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-01 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adrenergic ReceptorAgonistAlanineAsthmaAtherosclerosisBindingBiologicalBiological AssayCC chemokine receptor 1CCR1 geneCellsChemokine, OtherCollaborationsComplementComplexCoupledDataDeuteriumDevelopmentDiseaseDisulfidesElectron Spin Resonance SpectroscopyEpitopesFamilyFluorescenceFutureG-Protein-Coupled ReceptorsGTP-Binding ProteinsGoalsGraft RejectionHelix (Snails)Heterotrimeric GTP-Binding ProteinsHost DefenseHydrogenImmune responseImmune systemInfiltrationInflammatoryIntegral Membrane ProteinKnowledgeLeukocytesLigand BindingLigandsLocalizedMapsMass Spectrum AnalysisMediatingMembraneMethodsMolecularMultiple SclerosisMutagenesisPathogenesisPlayPoint MutationPublic HealthReceptor ActivationRelianceRheumatoid ArthritisRhodopsinRoleSideSignal TransductionSiteSite-Directed MutagenesisSpin LabelsSurfaceSystemTherapeuticTissuesTrainingWood materialWorkchemokinechemokine receptorcrosslinkear helixextracellularinsightmigrationmonocytemonocyte chemoattractant protein-3mutantreceptorreceptor bindingreceptor functionresearch studyresponsesmall molecule
项目摘要
DESCRIPTION (provided by applicant): Chemokines and their receptors are involved in both the innate and adaptive immune response; however, inappropriate activation or expression of chemokines and receptors has been identified in several diseases such as atherosclerosis, multiple sclerosis, asthma, and rheumatoid arthritis. Although the chemokine network is crucial to host defense, little is known about the molecular mechanism of receptor activation by ligand. Chemokine receptors belong to the family of Rhodopsin-like G-protein coupled receptors (GPCRs). GPCRs are characterized by 7-transmembrane spanning helices coupled intracellularly to a heterotrimeric G-protein. Agonist-induced activation of chemokine receptors results in conformational changes that trigger downstream signaling of the G-protein. To this end, the objectives set forth in this training plan aim to elucidate the molecular mechanism of activation of the chemokine receptor, CCR1, by the chemokine agonist, MCP-3. Like many chemokines and chemokine receptors, MCP-3 and CCR1 likely play a role in the pathogenesis of inflammatory diseases that involve monocyte infiltration. The specific aims of this proposal are as follows: (1) In collaboration with the Woods lab here at UCSD, we will use enhanced deuterium exchange with Mass Spectrometry (DXMS) to identify the interaction surfaces between the MCP-3:CCR1 complex. (2) Carry out mutagenesis on the extracellular loop regions of CCR1 to identify specific residues involved in ligand binding and activation. Separately, these two approaches will provide significant insight into the chemokine receptor-ligand interactions, but taken together, they provide a comprehensive analysis of CCR1:MCP-3 interactions. Therefore, identifying and understanding these particular interactions will aid the development of small molecule antagonists of CCR1, given its involvement in several diseases. RELEVANCE TO PUBLIC HEALTH: Chemokines play a major role in our immune system response; however, inappropriate activity of chemokines and receptors can result in inflammatory diseases such as atherosclerosis, multiple sclerosis, and rheumatoid arthritis. Therefore, the structural and functional knowledge gained from these studies of the chemokine receptor will contribute to our limited understanding of chemokine receptor-ligand activity and function. This information can guide therapeutic interference strategies in the treatment of inflammatory diseases.
描述(由申请人提供):趋化因子及其受体参与先天性和适应性免疫应答;然而,在几种疾病如动脉粥样硬化、多发性硬化、哮喘和类风湿性关节炎中已经鉴定出趋化因子及其受体的不适当活化或表达。虽然趋化因子网络对宿主防御至关重要,但对配体激活受体的分子机制知之甚少。趋化因子受体属于视紫红质样G蛋白偶联受体(GPCR)家族。GPCR的特征在于细胞内偶联至异源三聚体G蛋白的7跨膜跨螺旋。激动剂诱导的趋化因子受体活化导致构象变化,从而触发G蛋白的下游信号传导。为此,本培训计划中提出的目标旨在阐明趋化因子受体CCR 1被趋化因子激动剂MCP-3激活的分子机制。与许多趋化因子和趋化因子受体一样,MCP-3和CCR 1可能在涉及单核细胞浸润的炎性疾病的发病机制中发挥作用。该提案的具体目标如下:(1)与UCSD的Woods实验室合作,我们将使用增强的氘交换质谱(DXMS)来识别MCP-3:CCR 1复合物之间的相互作用表面。(2)对CCR 1的胞外环区域进行诱变,以鉴定参与配体结合和活化的特定残基。单独地,这两种方法将为趋化因子受体-配体相互作用提供重要的见解,但结合在一起,它们提供了CCR 1:MCP-3相互作用的全面分析。因此,识别和理解这些特定的相互作用将有助于开发CCR 1的小分子拮抗剂,因为它参与了几种疾病。与公共卫生的关系:趋化因子在我们的免疫系统反应中起主要作用;然而,趋化因子和受体的不适当活性可导致炎性疾病,如动脉粥样硬化、多发性硬化和类风湿性关节炎。因此,从这些趋化因子受体的研究中获得的结构和功能知识将有助于我们对趋化因子受体-配体活性和功能的有限理解。这些信息可以指导炎症性疾病治疗中的治疗干预策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CATHERINA L SALANGA其他文献
CATHERINA L SALANGA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CATHERINA L SALANGA', 18)}}的其他基金
Identification of Molecular Interactions Between a Chemokine Receptor and Ligand
趋化因子受体和配体之间分子相互作用的鉴定
- 批准号:
7901472 - 财政年份:2007
- 资助金额:
$ 2.97万 - 项目类别:
Identification of Molecular Interactions Between a Chemokine Receptor and Ligand
趋化因子受体和配体之间分子相互作用的鉴定
- 批准号:
7675387 - 财政年份:2007
- 资助金额:
$ 2.97万 - 项目类别:
Identification of Molecular Interactions Between a Chemokine Receptor and Ligand
趋化因子受体和配体之间分子相互作用的鉴定
- 批准号:
7331660 - 财政年份:2007
- 资助金额:
$ 2.97万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 2.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 2.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 2.97万 - 项目类别: